

## **Aelis Farma has participated in two symposiums marking World Down Syndrome Day**

**Bordeaux, March 21, 2023 – 5.45 pm CET – Aelis Farma** (ISIN: FR0014007ZB4 – Ticker: AELIS, eligible for PEA-PME equity savings plans), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, today announces its participation in two symposiums marking World Down Syndrome Day.

### **The 18<sup>th</sup> World Down Syndrome Day Colloquium (Bourg-en-Bresse, France, March 17-19, 2023)**

Pier Vincenzo Piazza, CEO of Aelis Farma, spoke on March 18 at the 18<sup>th</sup> World Down Syndrome Day Colloquium, organized by the AFRT ([Association Française pour la Recherche sur la Trisomie 21](#), the French Association for Research into Down Syndrome), on the theme of “Current pharmacological leads” and presented the progress made by AEF0217, which targets cognitive disorders associated with Down Syndrome.

### **The second ICOD symposium (Madrid, Spain, March 21, 2023)**

The [second ICOD \(Improving Cognition in Down Syndrome\) symposium](#), held at the Hospital de la Princesa in Madrid, is specifically dedicated to increasing knowledge about innovative therapeutic approaches to cognitive deficits in individuals with Down Syndrome and encouraging such individuals to take part in clinical studies targeting these disorders.

The symposium also allows interaction and discussions between families, associations of Down Syndrome individuals and clinicians to promote research in this field.

**Pier Vincenzo Piazza, CEO of Aelis Farma, said:** *“Our participation in these two events demonstrates our strong commitment to helping families and individuals with Down Syndrome by developing a treatment for cognitive deficits associated with this genetic condition. At these events, we were delighted to be able to share the progress made by our AEF0217 drug candidate, which is currently in a phase 1/2 clinical study that should be completed by the end of 2023. This study primarily aims to confirm AEF0217’s good safety and pharmacokinetics – already demonstrated in healthy volunteers – in people with Down Syndrome, and could also provide the first indications on AEF0217’s potential as a treatment for cognitive deficits. If the results are positive, this would be a major milestone in the development of a promising treatment that could considerably improve the quality of life of individuals with Down Syndrome, and maybe pave the way for the treatment of cognitive disorders associated with other neurodevelopmental diseases”.*

\*\*\*

## About the AEF0217 clinical program for treating cognitive disorders associated with Down Syndrome: the European ICOD project.

The phase 1/2 study with AEF0217 in Down Syndrome individuals follows the program of phase 1 clinical studies undertaken in healthy volunteers that demonstrated this new drug candidate's very favorable safety profile. It will be followed by a multicentric phase 2b study that should be launched in 2024 and will enable AEF0217's therapeutic potential in people with Down Syndrome to be confirmed. All these studies are part of the H2020 ICOD (*Improving COgnition in Down syndrome, Grant number 899986*) European project, which has received €6 million in funding from the European Commission to support AEF0217's clinical development in Down Syndrome. The ICOD project is being undertaken in collaboration with the Hospital del Mar Medical Research Institute (IMIM) in Barcelona (Spain) and Prof. Rafael de la Torre Fornell, project coordinator and principal investigator of the clinical trials, and also involves four additional clinical centers in Europe.

## About AELIS FARMA

Founded in Bordeaux in 2013, Aelis Farma is a biopharmaceutical company that is developing a new class of drugs, the Signaling Specific inhibitors of the CB<sub>1</sub> receptor of the endocannabinoid system (CB<sub>1</sub>-SSi). These CB<sub>1</sub>-SSi have been developed by Aelis Farma based on the discovery of a new natural brain defense mechanism by the team led by Dr. Pier Vincenzo Piazza, the Company's CEO, when he was Director of the INSERM Magendie Neurocenter in Bordeaux. By reproducing this natural mechanism, CB<sub>1</sub>-SSi appear to be capable of selectively inhibiting disease-related activity of the CB<sub>1</sub> receptor without disrupting its normal physiological activity. They thus have substantial potential for the treatment of numerous brain diseases.

Aelis Farma is developing two first-in-class clinical-stage drug candidates, AEF0117 for the treatment of disorders due to excessive cannabis use, currently in a phase 2b study in the United States, and AEF0217 for cognitive disorders, including those of Down Syndrome (Trisomy 21), currently in a phase 1/2 study in Spain. The Company also has a portfolio of innovative CB<sub>1</sub>-SSi for the treatment of other disorders associated with a dysregulation of the activity of the CB<sub>1</sub> receptor.

Aelis Farma leverages the talents of more than 20 highly qualified employees.

For more information, go to [www.aelisfarma.com](http://www.aelisfarma.com) and follow us on [LinkedIn](#) and [Twitter](#).



ISIN: FR0014007ZB4

Ticker: AELIS

Euronext Paris Compartment B

## Contacts

### AELIS FARMA

Pier Vincenzo Piazza  
CEO  
[contact@aelisfarma.com](mailto:contact@aelisfarma.com)

### NewCap

Dusan Oresansky/Aurélie Manavarere  
Investor Relations  
[aelis@newcap.eu](mailto:aelis@newcap.eu)  
+33 1 44 71 94 92

### NewCap

Arthur Rouillé  
Media Relations  
[aelis@newcap.fr](mailto:aelis@newcap.fr)  
+33 1 44 71 00 15

## Disclaimer

### Forward-looking statements

Some information contained in this press release are forward-looking statements, not historical data. These forward-looking statements are based on current beliefs, expectations, and assumptions, including, but not limited to, assumptions about Aelis Farma's current and future strategy and the environment in which Aelis Farma operates. They involve known and unknown risks, uncertainties, and other factors, which may cause actual results, performance or achievements, or industry results or other events, to differ materially from those described or implied by such forward-looking statements. These risks and uncertainties include those

set out and detailed in Chapter 3 "Risk Factors" of Aelis Farma's registration document approved by the Autorité des marchés financiers on 14 January 2022 under number I.22-003.

These forward-looking statements are made only as of the date of this press release and Aelis Farma expressly disclaims any obligation or undertaking to release any updates or corrections to the forward-looking statements included in this press release to reflect any change in expectations or events, conditions or circumstances on which any such forward-looking statement is based. Forward-looking information and statements are not guarantees of future performance and are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond Aelis Farma's control. Actual results could differ materially from those described in, or implied or projected by, forward-looking information and statements.